−440 KRW
−10.27 B KRW
13.72 M KRW
17.91 M
About VAXCELL-BIO THERAPEUTICS
Sector
Industry
Headquarters
Hwasun-gun
Website
Founded
2010
ISIN
KR7323990002
FIGI
BBG00WK5VH03
Vaxcell-Bio Therapeutics develops anti-cancer therapeutics. It specializes in immune cell therapy. The company was founded by Lee Jae-Jung on February 18, 2010 and is headquartered in Hwasun-gun, South Korea.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of 323990 is 10,000 KRW — it has decreased by −4.21% in the past 24 hours. Watch VAXCELL-BIO THERAPEUTICS stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on KRX exchange VAXCELL-BIO THERAPEUTICS stocks are traded under the ticker 323990.
323990 stock has fallen by −8.51% compared to the previous week, the month change is a −15.25% fall, over the last year VAXCELL-BIO THERAPEUTICS has showed a −55.16% decrease.
323990 reached its all-time high on Jan 7, 2021 with the price of 234,270 KRW, and its all-time low was 7,990 KRW and was reached on Oct 20, 2020. View more price dynamics on 323990 chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
323990 stock is 4.40% volatile and has beta coefficient of 1.04. Track VAXCELL-BIO THERAPEUTICS stock price on the chart and check out the list of the most volatile stocks — is VAXCELL-BIO THERAPEUTICS there?
Today VAXCELL-BIO THERAPEUTICS has the market capitalization of 229.65 B, it has decreased by −6.58% over the last week.
Yes, you can track VAXCELL-BIO THERAPEUTICS financials in yearly and quarterly reports right on TradingView.
323990 net income for the last quarter is −2.41 B KRW, while the quarter before that showed −2.45 B KRW of net income which accounts for 1.48% change. Track more VAXCELL-BIO THERAPEUTICS financial stats to get the full picture.
No, 323990 doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Dec 22, 2024, the company has 57.00 employees. See our rating of the largest employees — is VAXCELL-BIO THERAPEUTICS on this list?
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. VAXCELL-BIO THERAPEUTICS EBITDA is −12.61 B KRW, and current EBITDA margin is −79.19 K%. See more stats in VAXCELL-BIO THERAPEUTICS financial statements.
Like other stocks, 323990 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade VAXCELL-BIO THERAPEUTICS stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So VAXCELL-BIO THERAPEUTICS technincal analysis shows the strong sell today, and its 1 week rating is strong sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating VAXCELL-BIO THERAPEUTICS stock shows the sell signal. See more of VAXCELL-BIO THERAPEUTICS technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.